The immunology of renal cell carcinoma
CM Díaz-Montero, BI Rini, JH Finke - Nature Reviews Nephrology, 2020 - nature.com
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Previous studies have suggested that the gut microbiome influences the response to
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE …
LJ Padrón, DM Maurer, MH O'Hara, EM O'Reilly… - Nature medicine, 2022 - nature.com
Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …
[PDF][PDF] Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
RJ Motzer, PB Robbins, T Powles, L Albiges… - Nature medicine, 2020 - nature.com
We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN
Renal 101 trial (n= 886; NCT02684006), which demonstrated significantly prolonged …
Renal 101 trial (n= 886; NCT02684006), which demonstrated significantly prolonged …
[HTML][HTML] The pyroptosis-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer
W Shao, Z Yang, Y Fu, L Zheng, F Liu… - Frontiers in cell and …, 2021 - frontiersin.org
Gastric cancer (GC) is one of the leading causes of cancer-related deaths and shows high
levels of heterogeneity. The development of a specific prognostic model is important if we …
levels of heterogeneity. The development of a specific prognostic model is important if we …
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 …
Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1)
improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To …
improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To …